beta amyloid

[Asn23]-beta-Amyloid (1-42), Iowa mutation, is a biologically active peptide with increased aggregation propensity and fibril toxicity. This mutation involves the substitution of Aspartic acid (Asp) at position 23 with Asparagine (Asn), contributing to autosomal dominant Alzheimer's Disease and associated with severe cerebral amyloid beta-protein angiopathy (CAA) due to a missense alteration at position 694 of the amyloid precursor protein (APP) gene.

Amyloid beta-protein(1-40) Arctic variant (Ab40ARC (E22G)), featuring a glycine at position 22 (Gly22), is a peptide utilized in Alzheimer's disease research [1].

Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is an IgG2b, λ inhibitor derived from mice, targeting Amyloid-beta.

Anti-Amyloid Beta Antibody (DLX212) represents a highly specialized humanized monoclonal antibody specifically engineered to target various forms of Amyloid Beta (Aβ) with exceptional binding affinity. It effectively facilitates the measurable clearance of amyloid plaques across various preclinical experimental models to evaluate the reduction of neurotoxicity and the restoration of synaptic plasticity during strictly monitored laboratory observation periods and functional cognitive assays.

Anti-Amyloid Beta Antibody (CNTO 2125) is a recombinant humanized monoclonal antibody targeting human Amyloid Beta (Aβ/Amyloid Beta). Aβ is the core component of amyloid plaques in the Alzheimer's disease (AD) brain, generated from the cleavage of amyloid precursor protein (APP). CNTO 2125 specifically binds to Aβ with high affinity (e.g., EC50 ≈ 9.7 ng/mL), blocking the aggregation of Aβ monomers and promoting the clearance of existing plaques. By targeting the Aβ cascade, this antibody has the potential to protect neurons from Aβ-mediated neurotoxic damage, serving as a critical tool for researching the pathogenesis and immunotherapy of Alzheimer's disease. This antibody features a huIgG1 heavy chain and a hu-kappa light chain.

Anti-Amyloid Beta Antibody (scFv59) is a single-chain variable fragment (scFv) antibody targeting Amyloid-beta (Abeta). This product specifically recognizes oligomeric and fibrillar forms of Abeta and neutralizes Abeta-induced neurotoxicity. By blocking the self-aggregation of Abeta molecules and interfering with their interaction with neuronal surfaces, scFv59 inhibits amyloid plaque formation and associated synaptic damage.

Rutin (Quercetin 3-O-rutinoside), a flavonoid, has a variety of biological activities including antiallergic, anti-inflammatory, antiproliferative, and anticarcinogenic properties.

Deferoxamine Mesylate (DFOM) is an iron chelator and ferroptosis inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.

DAPT (LY-374973) is a γ-secretase inhibitor that inhibits total Aβ and Aβ42 (IC50=115/200 nM) and is orally active. DAPT is also a Notch inhibitor. DAPT induces cell differentiation, autophagy and apoptosis.

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Colivelin is a neuroprotective peptide and activator of STAT3. Colivelin is a hybrid peptide synthesized to enhance the neuroprotective effects of humanin (HN).

Resveratrol (SRT 501) is a polyphenolic natural product, a plant antitoxin with antioxidant and chemopreventive activities. Resveratrol has a wide range of targets including COX, SIRT, LOC, etc. Resveratrol induces autophagy and apoptosis.

CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM). CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells and dramatically inhibits and reverses the formation of β-amyloid Aβ42 fibril aggregates. CGP52411 can be used in studies about Alzheimer's diseases.

BMS 433796 is a γ-secretase inhibitor that demonstrates Aβ-lowering activity in a transgenic mouse model of Alzheimer's disease.

MK-3328 has a high affinity for β-Amyloid (IC50:10.5 nM), and can be used as a candidate PET ligand for clinical assessment of β-amyloid plaque load. MK-3328 is a potential treatment for Alzheimer's disease.

Rutin hydrate (Sophorin), a kind of glycoside, widely exists in many plants including citrus fruit.

PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD).

Fenlean (FLZ) is a tyrosine kinase Src inhibitor, a synthetic cyclic derivative of squamous amide from Annona glabra, with cytoprotective activity, which protects tyrosine hydroxylase function in a chronic MPTP/prostaglandin-type mouse model of Parkinson's disease.Fenlean inhibits the production of Aβ in the mitochondria, which may be useful in the study of age-related macular degeneration and Parkinson's disease. and Parkinson's.

L-Clausenamide is an alkaloid extracted from the leaves of the yellow bark (Clausena lansium (Lour) skeels) and can be used to improve cognitive function. L-Clausenamide inhibits beta-amyloid (Aβ) toxicity and prevents the formation of neurofibrillary tangles by inhibiting tau phosphorylation. L-Clausenamide has neuroprotective activity and can be used to modulate stimuli triggered by Aβ25-35. L-Clausenamide can be used to study neurological disorders like Alzheimer's disease.

DSS30 is a P25/CDK5 inhibitor.DSS30 acts by inhibiting the phosphorylation of amyloid precursor protein cleaving enzyme 1 (BACEl), which reduces the secretion of β-amyloid (Aβ).DSS30 can be used for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease.

Compound 5936-0108 may has modulationg effect on β-Amyloid.

BI-1408 is a modulator potent of γ secretase (IC50: 0.04 μM for Aβ42).

Glutaminyl Cyclase Inhibitor 1, a glutaminyl cyclase inhibitor with an IC50 of 0.5 μM, can be utilized for studying neurological disorders.

K 01-162 binds and destabilizes AβO (β-amyloid), with an EC50 of 80 nM.